Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

Journal of Clinical Pharmacology

Volumn 41, Issue 11, 2001, Pages 1206-1214

  Dowell, James A ^a,b   Korth Bradley, Joan ^a   Liu, Hanjiu ^a   King, S Peter ^a   Berger, Mark S ^a  

^a WYETH AYERST RESEARCH   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; DIPHENHYDRAMINE; GEMTUZUMAB OZOGAMICIN; PARACETAMOL;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; BLAST CELL; BLOOD SAMPLING; CANCER RECURRENCE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; EVALUATION; FEMALE; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARAMETER; PHASE 2 CLINICAL TRIAL; STRUCTURE ANALYSIS;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CELL ADHESION MOLECULES; ENEDIYNES; FEMALE; HUMANS; IMMUNOTOXINS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID; MALE; MEMBRANE GLYCOPROTEINS; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; RECURRENCE;

EID: 0034770328     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122012751     Document Type: Article

References (17)

1. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
2. Calicheamicins, a novel family of antitumor antibiotics: 1. Chemistry and partial characterization of 1I
3. Interaction of calicheamicin with DNA
4. Calicheamicin 1I and DNA: Molecular recognition process responsible for site-specificity
5. Specific abstraction of the 5′(S)- and 4′-deoxyribosyl hydrogen atoms from DNA by calicheamicin γ1I
6. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model
7. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogeneous leukemia
8. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
9. Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) in patients with CD33-positive acute myeloid leukemia in first relapse
10. Development of enzyme-linked immunosorbent assays in plasma allowing examination of the pharmacokinetics of gemtuzumab ozogamicin, a novel antibody-targeted chemotherapy, in patients with relapsed acute myeloid leukemia
11. A phase I monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide
12. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity
13. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias
14. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
15. A clinical trial of anti-idiotype therapy for B cell malignancy
16. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
17. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program